Results 21 to 30 of about 2,519,772 (150)

IL‐31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases and is farnesoid X receptor responsive in NASH

Hepatology, EarlyView., 2022
IL‐31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases Abstract Background and Aims Pruritus is associated with multiple liver diseases, particularly those with cholestasis, but the mechanism remains incompletely understood.
Jun Xu, Ya Wang, Mina Khoshdeli, Matt Peach, Jen‐Chieh Chuang, Julie Lin, Wen‐Wei Tsai, Sangeetha Mahadevan, Wesley Minto, Lauri Diehl, Ruchi Gupta, Michael Trauner, Keyur Patel, Mazen Noureddin, Kris V. Kowdley, Aliya Gulamhusein, Christopher L. Bowlus, Ryan S. Huss, Robert P. Myers, Chuhan Chung, Andrew N. Billin   +20 more
wiley   +1 more source

In Silico Prediction and Pharmacokinetic Comparison of Ursodeoxycholic Acid and Obeticholic Acid in the Management of Primary Biliary Cholangitis [PDF]

, 2021
Background: Primary Biliary Cholangitis (PBC) is a persistent liver disease. Ursodeoxycholic acid is used as a first-line treatment for the past two decades.
Dhanasekaran, Dhivya, Dhage, Manali Sudhir, Sabarathinam, Sarvesh, Ganamurali, Nila   +3 more
core   +1 more source

Reduction and stabilization of bilirubin with obeticholic acid treatment in patients with primary biliary cholangitis [PDF]

, 2020
Background & Aims: Total bilirubin is a predictor of survival in primary biliary cholangitis, with the main elevated component being direct bilirubin. The purpose of this post hoc analysis was to assess the efficacy and safety of obeticholic acid across ...
Leigh MacConell, Albert Parés, Mitchell Shiffman, MacConell, Leigh, Malecha, Elizabeth S., Gideon Hirschfield, Shiffman, Mitchell L., Liberman, Alexander, Hirschfield, Gideon, Victor Vargas, Vargas Blasco, Víctor, Shiffman, Mitchell, Parés Darnaculleta, Albert, Parés, Albert, Pietro Invernizzi, Alexander Liberman, Elizabeth S. Malecha, Vargas, Víctor, Invernizzi, Pietro   +18 more
core   +1 more source

Obeticholic Acid Forms Two Series of Isostructural Non-stoichiometric Channel Solvates

, 2022
The aim of this work was to investigate solid forms of an active pharmaceutical substance, obeticholic acid, and to characterize the discovered structures. Obeticholic acid is used to treat primary biliary cholangitis.
Miloš Václavík (13205255), Eliška Skořepová (1875496), Miroslav Šoóš (4025402), Morgane Poupon (1584682), Luděk Ridvan (4426162), Jan Jirát (9211182), Martin Babor (4025399)   +6 more
core   +1 more source

Impact of Obeticholic Acid and Moringaoleifera Leaf Extract on Arsenic induced Hepatotoxicity and Related Immunohistochemistry Changes in Adult Male Albino Rats [PDF]

International Journal of Medical Arts
Background:  A naturally occurring poison, arsenic can be found in food, soil, and water. Drinking water tainted with arsenic is the main way of exposure.
Fatma Noaman, Hamed Osman, Mohamed Abbas, Ashraf Emara   +3 more
doaj   +1 more source

Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study. [PDF]

, 2022
BACKGROUND & AIMS Nonalcoholic steatohepatitis (NASH) is a chronic, progressive fibrotic liver disease that can lead to cirrhosis. While liver biopsy is considered the reference standard for histologic diagnosis of NASH and staging of fibrosis, use in
Trylesinski, Aldo, Anstee, Quentin M, Goodman, Zachary, Loomba, Rohit, Ratziu, Vlad, Rinella, Mary, Natha, Macky, Dufour, Jean-François, Harrison, Stephen A, Younossi, Zobair, Shringarpure, Reshma, Bonacci, Martin, Granston, Tanya, Sanyal, Arun J, Venugopal, Aditya   +14 more
core   +2 more sources

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial [PDF]

Background Non-alcoholic steatohepatitis (NASH) is a common type of chronic liver disease that can lead to cirrhosis. Obeticholic acid, a farnesoid X receptor agonist, has been shown to improve the histological features of NASH.
Ratziu V, Shringarpure R, Campagna J, Harrison S, Dufour JF, Oliveira A, Boursier J, Graupera I, MacConell L, Younossi ZM, Geier A, Anstee QM, Goodman Z, Sheikh MY, Zaru L, Sanyal AJ, Sheridan D, Bedossa P, Kowdley KV, Shapiro D, Beckebaum S, Cortez-Pinto H, Knapple W, Mathurin P, Rinella M, Loomba R, Lawitz E, Montaono-Loza AJ, Abdelmalek MF, Trotter J, Newsome PN, Gluud LL, Mazzella G, Orr D, Bugianesi E   +34 more
core   +4 more sources

Therapies for non-alcoholic steatohepatitis

Liver Research, 2017
Current phase 3 trials for the treatment of non-alcoholic steatohepatitis (NASH) are discussed in this review. Modalities that are based on weight loss include therapeutic lifestyle changes, pharmacological weight loss drugs (e.g., orlistat), and ...
Winston Dunn
doaj   +1 more source

Primary Biliary Cholangitis and Bile Acid Farnesoid X Receptor Agonists

Diseases, 2020
Primary biliary cholangitis (PBC) is a chronic autoimmune liver disease characterized by the progressive destruction of the intrahepatic bile ducts. Currently, the first line drug for PBC is ursodeoxycholic acid (UDCA) characterized by anti-apoptotic ...
Ludovico Abenavoli, Anna Caterina Procopio, Sharmila Fagoonee, Rinaldo Pellicano, Marco Carbone, Francesco Luzza, Pietro Invernizzi   +6 more
doaj   +1 more source

A Placebo-controlled trial of obeticholic acid in primary biliary cholangitis [PDF]

, 2016
Item does not contain fulltextBACKGROUND: Primary biliary cholangitis (formerly called primary biliary cirrhosis) can progress to cirrhosis and death despite ursodiol therapy.
Marmon, T., Nevens, Frederik, FLOREANI, ANNAROSA, Erpecum, K.J. van, Nevens, F, Hirschfield, Gideon M., Kowdley, Kris V., Vargas, V., Kowdley, K. V., Bowlus, C, Strasser, Simone I., Vincent, C., Hirschfield, G. M., Pockros, Paul J, Erpecum, K.J. (Karel) van, Shiffman, M, Hohenester, Simon, Invernizzi, Pietro, Jones, D.E.J. (David), Pruzanski, Mark, Sheeron, S, Vincent, Catherine, Beuers, U. (Ulrich), Regula, J. (J.), Andreone, Pietro, Trauner, M, Hansen, Bettina, Marschall, H.U., Jones, D.E., Mazzella, Giuseppe, Van Erpecum, K. J., Marschall, Hanns-Ulrich, Jones, D. E., Marmon, T, Drenth, J.PH., Shiffman, M., Floreani, A, Beuers, U., Regula, J., Hirschfield, Gideon M, Pruzanski, M, Pencek, Richard, Marschall, HU, Trauner, M., Bowlus, Christopher, Drenth, J.P.H., Vargas, Victor, POISE Study Group, Nevens, F. (Frederik), Marschall, Hanns-Ulrich,, Shapiro, David, Pencek, R., Beuers, Ulrich, MacConell, L, Shiffman, Mitchell, Drenth, J.P.H. (Joost), Lindor, KD, Drenth, JPH, Hooshmand-Rad, R, Hansen, B, Kowdley, KV, Floreani, A. (Annarosa), Hirschfield, GM, Bowlus, C.L. (Christopher L.), Hirschfield, G.M. (Gideon), Vincent, C, MacConell, Leigh, Shah, H., Sheeron, S., Lindor, K. D., Pruzanski, M., Hohenester, S, van Erpecum, Karel J, Hooshmand-Rad, R., Luketic, V, Pencek, R, Lindor, Keith D, Invernizzi, P., Hansen, B.E. (Bettina), Marschall, H.-U., Macconell, L., Jones, David E, Trauner, Michael, Vincent, C. (Catherine), Regula, Jaroslaw, Lindor, Keith D., Strasser, S.I., Vargas, V, Strasser, S. (Simone), Kowdley, K.V., Marschall, H-U, Jones, DE, Sheeron, Shawn, van Erpecum, Karel J., Invernizzi, P. (Pietro), Luketic, V., Invernizzi, P, Hooshmand-Rad, Roya, Andreone, P. (Pietro), Pockros, Paul J., Pockros, PJ, Luketic, Velimir, Beuers, U, Floreani, A., Bowlus, C., Drenth, Joost P. H., Hooshmand Rad, R., Nevens, F., Pockros, P. J., Shapiro, D, Andreone, P., Pockros, P.J., Drenth, J. P. H., Regula, J, Mazzella, G, Hohenester, S., Hansen, B., Shah, H, Strasser, Simone I, van Erpecum, KJ, Jones, David E., Hirschfield, G.M., Drenth, Joost P H, Strasser, SI, Marschall, H-U., Strasser, S. I., Mazzella, G., Peccei, R.E. (Riccardo), Lindor, K.D., Marschall, H. U., Kowdley, Kris V, Shapiro, D., Marmon, Tonya, Shah, Hemant, Andreone, P, Lindor, K.D. (Keith), van Erpecum, K.J.   +136 more
core   +3 more sources